CYBER-INTELLIGENCE-HOUSE
19.11.2021 09:02:09 CET | Business Wire | Press release
Hoxhunt, a premium enterprise cybersecurity awareness training platform, and Cyber Intelligence House, a leading provider of cyber intelligence, today announced a first-of-its-kind partnership designed to equip organizations with unprecedented protection from email attacks leveraging advanced insight across their dark-web-to employee-inbox lifecycle.
Hoxhunt’s CEO, Mika Aalto stated:
“This partnership with Cyber Intelligence House will open a whole new category of proactive cybersecurity awareness. Their industry-leading Cyber Exposure Platform adds a superior breadth and depth of intelligence from the Darkweb, Deep web and cyberspace forums and marketplaces to our dynamic awareness platform, typically 16 times more data than other solutions. By connecting threat intelligence with awareness, we can transform insight into foresight. Just imagine knowing an attack is likely coming and being able to train your employees with simulations of the actual phishing templates hackers purchased for their attack”.
Cyber Intelligence House’s CEO, Mikko Niemela adds:
“We are very excited to be partnering with Hoxhunt. Their best-in-class Cyber Awareness and Training platform allows organisations to adapt and defend against the ever rising volume of cyber threats that our platform identifies”.
About Hoxhunt:
Hoxhunt is a People-First Cybersecurity Platform that protects organizations and their employees from the risk of cyber attacks. Hoxhunt’s cognitive automation maps individually adaptive training curriculum to each employee’s skill level for optimal engagement. Hoxhunt empowers individuals with the tools and confidence to recognize and respond to attacks dynamically over time.
Hoxhunt enables security teams with real-time visibility into threats so they can react fast and limit their spread. The entire platform is autonomous, freeing up considerable time for security teams to focus on what matters.
To learn more about Hoxhunt, please visit https://www.hoxhunt.com or email info@hoxhunt.com .
About Cyber Intelligence House:
Cyber Intelligence House is a leading cyber intelligence company specialised in helping cyber security professionals and law enforcement to assess and monitor cyber exposure from the dark web, deep web, data breaches and online-assets. It is the trusted provider to government and law enforcement agencies globally, including Interpol and UNODC.
Cyber Intelligence House’s Cyber Exposure Platform (CEP) provides the world’s most comprehensive Cyber Threat database with over 10 years of data. 24/7 and collection and storing of new data at a rate of ~600 pages per second. CEP delivers unrivalled search and alerting performance with Deep scanning of over 250 metadata factors and machine learning enabled categorization of threats to provide deep insights into potential cyber threats.
To learn more about Cyber Intelligence House, please visit https://www.cyberintelligencehouse.com or email info@cyberintelligencehouse.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom